Novartis AG (NVS)
| Market Cap | 205.45B |
| Revenue (ttm) | 49.94B |
| Net Income (ttm) | 17.60B |
| Shares Out | 2.00B |
| EPS (ttm) | 8.58 |
| PE Ratio | 11.67 |
| Forward PE | 12.46 |
| Dividend | $3.78 (3.66%) |
| Ex-Dividend Date | Mar 7, 2024 |
| Volume | 971,635 |
| Open | 102.80 |
| Previous Close | 103.27 |
| Day's Range | 102.46 - 103.19 |
| 52-Week Range | 92.35 - 120.92 |
| Beta | 0.51 |
| Analysts | Hold |
| Price Target | 121.25 (+17.62%) |
| Earnings Date | Oct 29, 2024 |
About NVS
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and ... [Read more]
Financial Performance
In 2023, Novartis AG's revenue was $46.66 billion, an increase of 7.36% compared to the previous year's $43.46 billion. Earnings were $14.85 billion, an increase of 113.52%.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for NVS stock is "Hold." The 12-month stock price forecast is $121.25, which is an increase of 17.62% from the latest price.
News
Novartis: launch of Morphosys drug by could be 2027 or later
Novartis' CEO said on Thursday that the delayed launch of blood-cancer drug pelabresib from the takeover of Morphosys could be achieved in 2027 or later, but any approval would depend on further safet...
Novartis Lifts Sales Outlook on Key Drugs, Pipeline Portfolio
The pharma company raised its guidance on revenue growth from its key treatments and expected drug launches, and now anticipates annual currency-adjusted sales to grow by 6% through 2028.
Novartis raises annual sales guidance until 2028
Novartis on Thursday raised its medium-term sales guidance, predicting 6% annual growth through 2028, driven by strong momentum of launched drugs and the prospect of upcoming market introductions.
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance upgraded to +6% CAGR 2023-2028 and +5% 2024-2029 Strong momentum in the business with 8 in-market brands with USD 3bn+ to USD 8bn+ pe...
Novartis ranks first in 2024 Access to Medicine Index
Basel, November 19, 2024 – Novartis has ranked first in the 2024 Access to Medicine Index (ATMI) report published today, highlighting the company's leadership in improving access to medicines around t...
Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate
Ratio to receive upfront, and potential milestones and tiered royalty payments BOSTON , Nov. 18, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative tec...
Cellares Appoints Ossama Eissa, Former Novartis, Lonza and Legend Biopharma Leader, as Chief Operating Officer
SOUTH SAN FRANCISCO, Calif. & BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cellares, the world's first Integrated Development and Manufacturing Organization (IDMO), and a leader in automated cell therapy manuf...
Schrödinger's stock pops as it enters collaboration pact with Novartis worth up to $2.5 billion
Schrödinger will receive $150 million upfront plus up to $2.3 billion in milestone and royalty payments.
Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced a multi-target collaboration and expanded software licensing agreement with Novartis.
Novartis CEO 'very confident' on sales target, doesn't fear patent cliff - newspaper
Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday, with the pharmaceuticals giant having nothing to fear from ...
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
On Tuesday, Novartis AG NVS reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the consensus of $12.76 billion.
Novartis: It's Not Too Late To Buy This Dividend Stock Now
Since my previous article in May, shares of Novartis AG have gone on to outperform the S&P 500 index. The drugmaker's revenue and core EPS topped analysts' expectations in Q3. Novartis' debt load rema...
Focus remains on R&D to drive growth of blockbuster drugs, says Novartis CEO
Vas Narasimhan, CEO at Novartis, discusses third-quarter results, and explains the strategy behind development of the company's most in-demand treatments.
Novartis: Strong Financials, But Market Skepticism Persists Amid Pipeline Concerns
Novartis reported a strong Q3 2024 with 9% YoY sales growth, largely driven by its top four drugs. Pluvicto and Leqvio saw significant growth but investor disappointment stemmed from a revenue adjustm...
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III trial ...
Novartis AG (NVS) Q3 2024 Earnings Call Transcript
Novartis AG (NYSE:NVS) Q3 2024 Earnings Conference Call October 29, 2024 9:00 AM ET Company Participants Sloan Simpson - Head of Investor Relations Vas Narasimhan - Chief Executive Officer Harry Kirs...
Novartis CEO on the impact of the U.S. election for pharma
Novartis CEO Vas Narasimhan talks to CNBC about the company's latest results and the potential impact of the U.S. election on the business.
Novartis Posts Results Above Estimates, Raises Outlook
Novartis (NVS) on Tuesday posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali.
Novartis Lifts Guidance Again After Key Drugs Help Results
The pharmaceutical giant raised its full-year guidance for the third time this year after higher third-quarter profit and sales topped analysts' expectations, boosted by revenue from its key drugs.
Novartis hikes FY forecast after Q3 profit beat
Novartis posts Q3 earnings with 10 per cent sales growth and 20 per cent core income growth. The drug maker has also hiked its FY guidance.
Novartis: we are exploring obesity drugs but other areas provide growth for years
Novartis said on Tuesday it was doing early research on next-generation obesity drugs that could be more tolerable or given at longer intervals but its current focus on other disease areas would provi...
Novartis lifts 2024 guidance for 3rd time on wider use of its drugs
Swiss drugmaker Novartis raised its 2024 earnings guidance for the third time on Tuesday, driven by wider use of its prescription drugs.
Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance
Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +10% (cc 1 , +9% USD) with core operating income up +20% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (...
Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash
Monte Rosa Therapeutics, Inc. secured a $150 million upfront partnership with Novartis to develop MRT-6160 for immune-mediated conditions, with potential $2.1 billion in milestone payments. Initial da...
Novartis AG (NVS) Renal Portfolio Update Call Transcript
Novartis AG (NYSE:NVS) Renal Portfolio Update Conference Call October 28, 2024 8:00 AM ET Company Participants Sloan Simpson - Head, Investor Relations Shreeram Aradhye - President, Global Drug Devel...